Insert Program or Hospital Logo Introduction Melanoma is notoriously resistant to chemotherapy. While surgical resection and adjuvant chemotherapy can.

Slides:



Advertisements
Similar presentations
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in HER2- Positive, First-Line Metastatic Breast Cancer (MBC) Baselga.
Advertisements

Clinical Trial Designs for the Evaluation of Prognostic & Predictive Classifiers Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer.
 DISCUSSION Number of resected lymph nodes in esophageal surgery has been previously discussed as for its probable impact on patients’ survival [4]. The.
ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.
Expression profiles for prognosis and prediction Laura J. Van ‘t Veer The Netherlands Cancer Institute, Amsterdam.
Re-Examination of the Design of Early Clinical Trials for Molecularly Targeted Drugs Richard Simon, D.Sc. National Cancer Institute linus.nci.nih.gov/brb.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
CRC-1 The Need for 3rd-Line Therapy in Non-Small Cell Lung Cancer Frances A. Shepherd, MD Scott Taylor Chair in Lung Cancer Research Princess Margaret.
Successful treatment of pediatric desmoid tumors using hydroxyurea Naomi Balamuth, M.D. Richard Womer, M.D. November 13, 2008.
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
Enhancement Of T-Cell Immunity To Osteosarcoma By Modulation Of Programmed Death Receptor Pathway Pooja Hingorani, Danielle Lussier, Joseph Blattman.
Eleni Galani Medical Oncologist
Mak KS, 1 Miller RC, 2 Krishnan S, 3 Laperriere N, 4 Micke O, 5 Rutten I, 6 Kadish SP, 7 Ozsahin M, 8 and Mirimanoff RO 8 1 Harvard Medical School, Boston,
Choice of chemotherapy in the treatment of metastatic squamous cell carcinoma of the anal canal. Eng C1, Rogers J2, Chang GJ3, You N3, Das P4, Rodriguez-Bigas.
Kerrington Smith, M.D. CTOS Nov 14, 2008
Low dose chemotherapy with insulin (Insulin Potentiation Therapy) in combination with hormone therapy for treatment of castration resistant prostate cancer.
Annual prostate cancer symposium February 23, 2013 The Kimmel Cancer Center, Philadelphia, PA 2nd “ Novel Therapeutic Strategies for Prostate Cancer ”
Cathy Eng M.D., Salil Sethi M.D., George J.Chang, M.D., Miguel A. Rodriguez-Bigas, M.D., John M. Skibber, M.D., Jianjun Shen Ph.D., Jijiang Zhu Ph.D.,
Sgroi DC et al. Proc SABCS 2012;Abstract S1-9.
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC) Victor.
Metabolic Syndrome and Recurrence within the 21-Gene Recurrence Score Assay Risk Categories in Lymph Node Negative Breast Cancer Lakhani A et al. Proc.
Immunotherapy Sara Engh & Tenzin Yiga. Role of the Immune system ➔ Defends against pathogens such as bacteria, fungi, and viruses that enter the body.
An Assessment of Factors Affecting Outcome in Patients Presenting with Metastatic Soft Tissue Sarcoma Peter Ferguson MD1,2, Benjamin Deheshi MD1,2, Anthony.
The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.
HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF.
High Cereblon Protein Expression Correlates with Improved Response and Survival in Myeloma Patients Treated with Lenalidomide 1 Cereblon Expression Predicts.
INCREASED EXPRESSION OF PROTEIN KINASE CK2  SUBUNIT IN HUMAN GASTRIC CARCINOMA Kai-Yuan Lin 1 and Yih-Huei Uen 1,2,3 1 Department of Medical Research,
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
Clinical variables, pathological factors, and molecular markers for enhanced soft tissue sarcoma prognostication G. Lahat, B. Wang, D. Tuvin, DA. Anaya,
The treatment of metastatic squamous cell carcinoma (SCCA) of the anal canal: A single institution experience P. Pathak, B. King, A. Ohinata, P. Das, C.H.
Heat Shock Protein 90 (HSP90) is over-expressed in p16 negative oropharyngeal squamous cell carcinoma and its inhibition in vitro potentiates the effects.
1 News from American Society of Clinical Oncology Meeting June 2011 (Lung and Skin) Paul Donnellan Consultant Medical Oncologist Galway University Hospitals.
Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.
Correlation of Hand-Foot Skin Reaction (HFS) with Treatment Efficacy in Pancreatic Cancer (PC) Patients (pts) Treated with Gemcitabine/Capecitabine plus.
Mamoun A. Rahman Surgical SHO Mr Osborne’s team. Introduction Blood transfusion: -Preoperative ( elective) -Intra/postoperative ( urgent) Blood transfusion.
Pre-Operative Therapy for Borderline Resectable Pancreatic Cancer: The Potential Role of Chemotherapy Robert A. Wolff, M.D. Associate Professor of Medicine.
Scott Kopetz, MD, PhD Department of Gastrointestinal Medical Oncology
Introduction Patients and Methods Results Conclusion Table 1. Baseline characteristics of the 108 patients included in the biomarker analysis. Objectives.
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer ? N. Perez-Staub, B. Chibaudel, A. Figer, A. Cervantes,
Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.
Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.
Operative Management of Osteosarcoma Patients with Pulmonary Metastasis Jen Kramer, MD R2 Swedish Medical Center February 2011.
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
What Factors Predict Outcome At Relapse After Previous Esophagectomy And Adjuvant Therapy in High-Risk Esophageal Cancer? Edward Yu 1, Patricia Tai 5,
Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.
Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.
Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.
AR-V7 Splice Variant in Prostate Cancer : Taking Centre Stage
Evaluating the Clinical Outcomes of Sixty-Three Patients Treated with Gamma Knife as Salvage Therapy for Glioblastoma Multiforme Erik W Larson, Halloran.
Results of Definitive Radiotherapy in Anal Canal Carcinoma
SD Walter MD1, T Mahten MD2, JW Harbour MD1,3
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
Prognosis of younger patients in non-small cell lung cancer
EMT inducing transcription factor SIP1: a predictive biomarker of colorectal cancer survival and recurrence? A Patel, R Sreekumar, R Bhome, KA Moutasim,
Taipei Veterans General Hospital,
Intervista a Lucio Crinò
Impact of Formal Methods in Biology and Medicine
Impact of Formal Methods in Biology and Medicine
Improved survival outcomes after resection of ductal adenocarcinoma in the body and tail of the pancreas: A single center 10 years’ experience Seong.
Treatment of human MCC tumors with intralesional IFNβ is associated with MHC-I upregulation. Treatment of human MCC tumors with intralesional IFNβ is associated.
Neoadjuvant Adjuvant Curative Palliative
Published online September 20, 2017 by JAMA Surgery
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma1 Phase 3 Randomized Study of Ipilimumab (IPI) plus Dacarbazine (DTIC) vs DTIC.
Coiffier B et al. Proc ASH 2011;Abstract 265.
Increased frequency and number of KLL-specific clonotypes in tumors is associated with improved MCC-specific survival. Increased frequency and number of.
DO NOT POST #4054 Gene expression Difference (GED) Revealed Immune Function Gene UP- or Down-regulation as Tumor-associated Inflammatory Cell (TAIC) Infiltration.
Presentation transcript:

Insert Program or Hospital Logo Introduction Melanoma is notoriously resistant to chemotherapy. While surgical resection and adjuvant chemotherapy can be curative in the very early stages of disease, the prognosis for patients with metastatic melanoma remains extremely poor. Median survival patients ranges from 6 to 9 months, with 5- year survival rates of less than 4% (1). Variable responses to biotherapies, including the IFNs and IL-2, provide intriguing avenues for further study. IL-2 activates the body’s innate response, boosting the patient’s immune system to fight the tumor (2). Systemic IL-2 treatment has provided significant clinical benefit in a minority of melanoma patients, leading to complete response in approximately 6% and partial response rates in an additional 10% of patients (3). However, the toxic side effects of IL-2 therapy limit its use to patients with higher performance status levels which remains an obstacle to widespread treatment with IL-2. As of yet, no reliable markers exist to predict which patients will respond to IL-2 immunotherapy. IL-24 and IL-2R beta may predict melanoma patient response to high dose IL-2 immunotherapy Emily Y. Jen (PGY3), Elizabeth A. Grimm Department of Melanoma Medical Oncology, M.D. Anderson Cancer Center, Houston, Texas Results The 5 year survival rate (with either complete or partial responses) in this small patient set was 20% (i.e. 80% of patients died of their disease within 5 years). The 10 year durable response rate was 10% (Table 1). These numbers are similar to the available national statistics for melanoma immunotherapy patients. 3 out of 4 patients who were alive at 5 years and 1 out of 2 patients with long term survival (10+ years) stained positive for both IL-24 and IL-2R beta (representative staining shown in Figure 1b). The other long term survivor stained positive only for IL-2R beta. All 3 patients who stained positive for both markers survived at least 5 years. Independently, IL-24 did not show significant correlation with patient survival at 5 or 10 years. IL-2R beta did show a correlation coefficient of 0.68 and 0.45 at 5 years and 10 years respectively, and positive staining for both IL-24 and IL- 2Rb within the same tumor correlated well with patient survival at 5 years (Table 2); however the significance of these correlations is reduced because of the small sample size. Abstract We have previously shown in vitro that some melanoma cell lines possess IL-2R chains, especially IL-2R beta. Of these, several upregulate IL-24 protein production resulting in subsequent growth suppression in melanoma tumor cells. IL- 24 is an anti-tumor cytokine that is known to cause apoptosis and growth suppression in several different cancers (4,5). Thus one mechanism of clinically effective IL-2 therapy may be the direct action of IL-2 on a biologically distinct subset of melanoma cells leading to upregulation of the tumor suppressor IL-24. We hypothesize that the presence of IL-2R beta and IL-24 on patient tumors correlates with increased survival, and therefore they may be useful as predictive markers for response to high dose IL-2 therapy. Experimental Design Melanoma tumor biopsy samples from 20 stage III-IV melanoma patients who received IL-2 immunotherapy were immunohistochemically stained for both IL-2R beta and IL- 24 and retrospectively compared to patient outcome. Work in Progress Based on our preliminary data, the study was extended in collaboration with the John Wayne Institute (JWI), Santa Monica, CA to include a large tissue microarray (Figure 2). This TMA includes 158 stage III melanoma patients prospectively being followed for recurrence free survival, as well as 195 positive and negative controls and is being studied for scores of potential markers. Of these 158 patients, 86 underwent high dose IL-2 immunotherapy. The data analysis from this study is ongoing. The stained slides are sent to JWI where they are evaluated for overall and disease free survival. Using this TMA, we have confirmed that IL-24 does not independently correlate with patient survival. Evaluation of IL-2R beta staining is currently in process and statistics will be run to determine whether the presence of IL-2R beta alone or both IL-2R beta and IL-24 together correlate with prolonged patient survival. References 1.American Cancer Society Statistics Grimm EA, et al, J Exp Med 1982;155: Atkins MB, et al, Cancer J Sci Am 2006; 6:S11 4.Chada S, et al, Int Immunopharmacol 2004; 4:649 5.Fisher PB, et al, Cancer Biol Ther 2003; 2:S23 Texas Pediatric Society Electronic Poster Contest Human melanoma H&E staining mIgG (neg control) CD68 (pos control) m  hIL-2R beta m  hIL-24 Patient 5 year survival 10 year survivalIL-24 IL-2R beta 1No No +- 11Yes -+ 12No -+ 13No -- 14No +- 15YesNo++ 16No -- 17No +- 18Yes ++ 19No -+ 20YesNo++ Correlation with patient survival Correlation coefficient IL-24 at 5 years IL-2Rbeta at 5 years IL-24 at 10 years IL-2Rbeta at 10 years Both at 5 years Both at 10 years Figure 2. John Wayne Institute Tissue Microarray Figure 1a. Figure 1b. Table 1. Patient survival and tumor staining Table 2. Marker staining correlation with patient survival